Nuwellis, Inc. (NASDAQ:NUWE) Sees Large Decrease in Short Interest

Nuwellis, Inc. (NASDAQ:NUWE) was the target of a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 106,200 shares, a decrease of 32.2% from the August 15th total of 156,700 shares. Approximately 9.7% of the company’s shares are short sold. Based on an average daily volume of 424,900 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

A number of analysts recently commented on NUWE shares. Roth Mkm reaffirmed a “buy” rating and issued a $17.00 price target on shares of Nuwellis in a research note on Tuesday, August 13th. Roth Capital raised shares of Nuwellis to a “strong-buy” rating in a research report on Monday, July 29th.

Nuwellis Stock Up 1.5 %

Shares of Nuwellis stock traded up $0.02 on Monday, reaching $1.38. The company’s stock had a trading volume of 124,206 shares, compared to its average volume of 232,663. The company has a market capitalization of $712,080.00, a price-to-earnings ratio of 0.00 and a beta of 0.42. Nuwellis has a 52 week low of $1.00 and a 52 week high of $58.80. The firm’s fifty day simple moving average is $2.39 and its two-hundred day simple moving average is $7.43.

Nuwellis (NASDAQ:NUWE) last posted its earnings results on Tuesday, August 13th. The company reported ($18.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.49) by ($9.36). Nuwellis had a negative net margin of 232.24% and a negative return on equity of 1,716.60%. The company had revenue of $2.19 million for the quarter, compared to the consensus estimate of $1.90 million. As a group, research analysts predict that Nuwellis will post -9.91 EPS for the current year.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.